A. Feyereislova

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · The Lancet · 2010 · 7.2K citations · Full text

Surgical Oncology, Chemotherapy Versus Chemotherapy, Gastrointestinal Oncology +8

Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology · 2003 · 2.9K citations

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith, Marion Procter, Richard D. Gelber et al. · The Lancet · 2007 · 1.5K citations

Breast Oncology, Medicine, Adjuvant Chemotherapy +6

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Luca Gianni, W. Eiermann, Alexey Manikhas et al. · The Lancet · 2010 · 1.2K citations

Noah Trial, Breast Oncology, Oncology +7

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Bella Kaufman, John R. Mackey, Michael Clemens et al. · Journal of Clinical Oncology · 2009 · 848 citations · Full text